Advanced Cardiac Therapeutics Company Profile

00:01 EST 14th December 2018 | BioPortfolio

Headquartered in Laguna Beach, California, USA, ACT specializes in advanced irrigated cardiac catheter ablation systems with proprietary temperature-sensing technology based on microwave radiometry.

News Articles [1710 Associated News Articles listed on BioPortfolio]

Advanced Cardiac Therapeutics, Inc. change sa dénomination pour devenir EPIX Therapeutics, Inc.

Annonce l'approbation de la FDA pour commencer à recruter des sujets atteints de fibrillation auriculaire persistante dans une étude IDE mondiale visant à évaluer le Read more...

Deals this week: Impact Therapeutics, Sienna Biopharmaceuticals, Advanced Proteome Therapeutics

Impact Therapeutics has raised $30m through a series C financing round from Decheng Capital (Decheng). Existing investor Lilly Asian Ventures (LAV)...Read More... The post Deals this week: Impact The...

DME Express Acquires Maryland-Based Advanced Therapeutics

DME Express, a leading technology enabled provider of medical equipment solutions to the hospice industry, has completed its acquisition of Maryland-based Advanced Therapeutics

Study compares programming strategies used in implanted cardiac defibrillators

Sudden cardiac death is a common cause of death in patients with congenital or acquired heart disease. An implanted cardiac defibrillator can effectively put a stop to any underlying cardiac arrhythmi...

FDA clears Medicalgorithmics' cardiac rehabilitation system

The FDA has granted Medicalgorithmics and its US unit Medi-Lynx Cardiac Monitoring 510(k) clearance for the PocketECG cardiac -More- 

Osiris Therapeutics, Inc. to Present Advanced Clinical and Scientific Abstracts at Symposium on Advanced Wound Care (SAWC) Fall Meeting, November 2-4, 2018, in Las Vegas, Nevada

COLUMBIA, Md., Oct. 30, 2018 (GLOBE NEWSWIRE) -- Osiris Therapeutics, Inc. (NASDAQ: OSIR), a regenerative medicine company focused on developing and marketing products for wound care, orthopedics, ...

China’s Beigene Teams up With Springworks to Target Advanced Solid Tumors

SpringWorks Therapeutics and BeiGene, Ltd. have teamed up to develop therapeutics that will target advanced solid tumors that contain RAS mutations, as well as other MAPK aberrations.

Fifth-Generation Cardiac Troponin Assays Compared

Cardiac troponin I (cTnI) and cardiac troponin T (cTnT) are highly specific biomarkers of myocardial injury. The 99th percentile upper...

PubMed Articles [3177 Associated PubMed Articles listed on BioPortfolio]

Cardiac MRI for the evaluation of oncologic cardiotoxicity.

Cancer therapeutics-related cardiac dysfunction (CTRCD) is a well-established adverse effect resulting from a number of cancer therapeutics. Newer immunotherapy has been associated with cardiomyopathy...

Adherence to Advanced Cardiovascular Life Support (ACLS) Guidelines During In-Hospital Cardiac Arrest Is Associated With Improved Outcomes.

Identifying modifiable factors associated with survival following in-hospital cardiac arrest is crucial. The purpose of this study was to determine the extent to which adherence to the 2010 American H...

Trends Over Time in Drug Administration During Adult In-Hospital Cardiac Arrest.

Clinical providers have access to a number of pharmacologic agents during in-hospital cardiac arrest. Few studies have explored medication administration patterns during in-hospital cardiac arrest. He...

LVAD Pulsatility Assesses Cardiac Contractility: In Vitro Model Utilizing the Total Artificial Heart and Mock Circulation.

There is a need for a consistent, reproducible, and cost-effective method of determining cardiac recovery in patients who receive emerging novel therapeutics for advanced and end-stage heart failure (...

Novel molecular therapeutic targets in cardiac fibrosis: A brief overview.

Cardiac fibrosis, characterized by excessive accumulation of extracellular matrix, abolishes cardiac contractility, impairs cardiac function and ultimately leads to heart failure. In recent years, sig...

Clinical Trials [8216 Associated Clinical Trials listed on BioPortfolio]

Impact of Ibis on Patients With Advanced COPD

The purpose of this research is to determine if Ibis™, a digital therapeutics solution developed by Senscio Systems, reduces the emergency room visits and hospitalizations of patients wi...

An Extension Study for T-1101 (Tosylate) to Treat Advanced Refractory Solid Tumorsfor

T-1101 is a novel anti-cancer agent being developed by Taivex Therapeutics Corporation, and is being studied in a phase I dose escalation trial, protocol TAI-001. That trial's primary aim ...

A Study of BBI503 in Combination With Selected Anti-Cancer Therapeutics in Adult Patients With Advanced Cancer

This is an open label, multi-center, Phase 1/2 study of BBI503 administered in combination with selected anti-cancer therapeutics in adult patients with advanced cancer. The goal of the st...

A Trial to Find Safe and Active Doses of an Investigational Drug CX-072 for Patients With Solid Tumors or Lymphomas

The purpose of this first-in-human study of CX-072 is to characterize the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD) and antitumor activity of CX-072 administered i...

HDL Acute Lipid Optimization in Homozygous Familial Hypercholesterolemia

Assess the effect on coronary atheroma of serial infusions of autologous selectively delipidated HDL/preβ enriched plasma following use of HDL Therapeutics PDS-2™ System

Companies [2408 Associated Companies listed on BioPortfolio]

Advanced Cardiac Therapeutics, Inc.

Headquartered in Laguna Beach, Calif., privately held Advanced Cardiac Therapeutics, Inc. specializes in advanced irrigated cardiac catheter ablation systems with proprietary temp...

Advanced Cardiac Therapeutics

Headquartered in Laguna Beach, California, USA, ACT specializes in advanced irrigated cardiac catheter ablation systems with proprietary temperature-sensing technology based on microwave radiometr...

Cardiac Insight, Inc.

Cardiac Insight, Inc. ( is a U.S. developer of advanced body-worn digital health care information devices for cardiology, respiratory and other complex ...

Medicomp, Inc.

Medicomp, Inc., founded in 1981, designs, develops and provides advanced cardiac monitoring products and services using the most sophisticated and reliable ambulatory heart-monitoring systems availabl...


Research and development of therapeutics based on signaling pathways in cardiac, hypertrophy, myosin heavy chain research and gene/protein expression profiling using its human cardiac tissue bank.

More Information about "Advanced Cardiac Therapeutics" on BioPortfolio

We have published hundreds of Advanced Cardiac Therapeutics news stories on BioPortfolio along with dozens of Advanced Cardiac Therapeutics Clinical Trials and PubMed Articles about Advanced Cardiac Therapeutics for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Advanced Cardiac Therapeutics Companies in our database. You can also find out about relevant Advanced Cardiac Therapeutics Drugs and Medications on this site too.

Quick Search


Corporate Database Quicklinks

Searches Linking to this Company Record